Maravai Lifesciences Holdings, Inc. (MRVI)
NASDAQ:MRVI
Top Page
Maravai Lifesciences Holdings
(NASDAQ:MRVI)
Select Model
Select Model
Rating:53Neutral
Price Target:
$3.00
▲(6.01% Upside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by weak recent financial performance (steep revenue decline, large losses, and 2025 cash burn) despite improved leverage. Offsetting this, the latest earnings call provided comparatively strong turnaround signals (positive 2026 EBITDA outlook and sizable cost reductions) and the technical trend is moderately constructive with price above major moving averages.
Positive Factors
High-margin Cygnus segment
Cygnus delivers persistently high adjusted EBITDA margins (~66–67%) and modest revenue growth, providing a durable cash-generative core. That strong margin profile supports company-level profitability resilience, funds reinvestment, and helps offset volatility in lower-margin segments over the medium term.
Negative Factors
Steep multi-year revenue contraction
A ~74% revenue drop in 2025 on top of earlier declines reduces scale and erodes fixed-cost absorption, pressuring gross margins and long-term profitability. Restoring top-line momentum is required to sustain margin improvements; prolonged revenue weakness risks structural shrinkage in market share and customer activity.
Read all positive and negative factors
Positive Factors
Negative Factors
High-margin Cygnus segment
Cygnus delivers persistently high adjusted EBITDA margins (~66–67%) and modest revenue growth, providing a durable cash-generative core. That strong margin profile supports company-level profitability resilience, funds reinvestment, and helps offset volatility in lower-margin segments over the medium term.
Read all positive factors
Maravai Lifesciences Holdings (MRVI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$727.50M
Dividend YieldN/A
Average Volume (3M)1.66M
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth-30.56%
EPS Growth48.79%
CountryUS
Employees570
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding146,383,160
10 Day Avg. Volume2,003,886
30 Day Avg. Volume1,659,398
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.22
Price to Sales (P/S)2.54
P/FCF Ratio-6.67
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue3.27
Enterprise Value/Gross Profit18.19
Enterprise Value/Ebitda-4.13
Forecast
1Y Price Target
$4.00Price Target Upside41.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$204.75M
Maravai Lifesciences Holdings Business Overview & Revenue Model
Company Description
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company'...
How the Company Makes Money
Maravai makes money by selling consumables, custom-manufactured materials, and contracted services to pharmaceutical/biotechnology companies, diagnostic developers, and research customers.
Key revenue streams include:
1) Nucleic Acid Production a...
Maravai Lifesciences Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyMaravai Lifesciences Holdings Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call conveyed a clear operational turnaround: management exceeded cost-savings targets (> $65M), returned to positive adjusted EBITDA in Q4, and provided constructive 2026 guidance (revenue growth and a materially positive adjusted EBITDA outlook). Product momentum (ModTail, GMP enzymes, mRNAbuilder, IVT kits) and Cygnus' strong margins were highlighted as durable strengths. Headwinds remain, including sizable GAAP losses driven by impairment and restructuring charges, continued full-year negative adjusted EBITDA in 2025, outstanding leverage, and order lumpiness that can produce volatility. Overall, the tone is optimistic about returning to sustained profitability in 2026 while acknowledging near-term balance-sheet and GAAP earnings challenges.Positive Updates
Full-Year Revenue and Q4 Performance
Full-year 2025 revenue of $185.7M (beat guidance by ~$0.7M). Q4 2025 revenue $49.9M; excluding $14.3M of high-volume CleanCap sales in Q4 2024, Q4 revenue grew 18% year-over-year.
Negative Updates
Large GAAP Net Losses and Impairment Charges
Q4 2025 GAAP net loss before noncontrolling interest was $63M (vs $46.1M in Q4 2024), which included a $25.8M noncash intangible asset impairment and $12.1M of noncash restructuring charges. Full-year GAAP net loss was $230.8M (vs $259.6M in 2024).
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue and Q4 Performance
Full-year 2025 revenue of $185.7M (beat guidance by ~$0.7M). Q4 2025 revenue $49.9M; excluding $14.3M of high-volume CleanCap sales in Q4 2024, Q4 revenue grew 18% year-over-year.
Read all positive updates
Company Guidance
Management guided 2026 revenue of $200–$210 million (up 8–13% vs. 2025’s $185.7M), with TriLink targeting low‑double‑digit growth at the midpoint and Cygnus low‑ to mid‑single‑digit growth, and full‑year adjusted EBITDA of $18–$20 million (an improvement of $50–$52M versus 2025). They expect roughly 1,200 basis points of gross margin expansion, total operating expenses down ~13%, G&A down ~18%, sales & marketing down ~13% and modestly higher R&D; modeling assumptions include net interest expense of $15–$17M, depreciation & amortization of $50–$52M, stock‑based compensation of $26–$28M, fully converted share count ~261M and net capex of $4–$6M. Management also noted they exceeded their cost‑saving target (now >$65M annualized vs. prior >$50M), reported Q4 adjusted EBITDA of $0.536M, expect positive adjusted EBITDA and positive cash flow in 2026, and executed a voluntary $50M debt repayment in Q1 (after year‑end cash of $216.9M and long‑term debt of $294.2M).Maravai Lifesciences Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
56
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 185.74M | 259.19M | 288.94M | 883.00M | 799.24M |
| Gross Profit | 33.39M | 108.31M | 140.20M | 714.04M | 658.68M |
| EBITDA | -147.11M | -156.92M | 712.41M | 609.99M | 585.78M |
| Net Income | -130.77M | -144.85M | -119.03M | 220.21M | 182.04M |
Balance Sheet | |||||
| Total Assets | 770.58M | 1.01B | 1.49B | 2.28B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 216.89M | 322.40M | 574.96M | 632.14M | 551.27M |
| Total Debt | 35.58M | 376.69M | 610.97M | 585.26M | 575.22M |
| Total Liabilities | 397.87M | 431.04M | 697.57M | 1.38B | 1.37B |
| Stockholders Equity | 212.38M | 325.29M | 416.75M | 545.22M | 315.50M |
Cash Flow | |||||
| Free Cash Flow | -70.72M | -22.19M | 60.67M | 518.89M | 353.72M |
| Operating Cash Flow | -57.57M | 7.46M | 126.22M | 535.98M | 368.57M |
| Investing Cash Flow | -31.41M | -24.32M | -122.31M | -267.61M | 105.66M |
| Financing Cash Flow | -16.50M | -235.71M | -61.09M | -187.50M | -159.05M |
Maravai Lifesciences Holdings Technical Analysis
Negative
2.83
Price Trends
3.29
Negative
3.41
Negative
3.05
Negative
Market Momentum
-0.13
Positive
33.88
Neutral
8.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Negative. The current price of 2.83 is below the 20-day moving average (MA) of 3.22, below the 50-day MA of 3.29, and below the 200-day MA of 3.05, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 33.88 is Neutral, neither overbought nor oversold. The STOCH value of 8.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MRVI.
Maravai Lifesciences Holdings Risk Analysis
Maravai Lifesciences Holdings disclosed 75 risk factors in its most recent earnings report. Maravai Lifesciences Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Maravai Lifesciences Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.78B | -5.25 | -43.17% | ― | -16.50% | 33.02% | |
53 Neutral | $727.50M | ― | -51.07% | ― | -30.56% | 48.79% | |
52 Neutral | $718.12M | -3.27 | -102.59% | ― | ― | -5.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.32B | -5.79 | -39.69% | ― | -27.61% | -69.49% | |
50 Neutral | $872.13M | -16.06 | -16.30% | ― | ― | 8.16% | |
47 Neutral | $1.14B | -0.42 | 536.36% | ― | -12.52% | -82.84% |
* Healthcare Sector Average
MRVI
Maravai Lifesciences Holdings
2.83
0.62
28.05%
KURA
Kura Oncology
8.34
1.82
27.91%
IMTX
Immatics
9.84
5.67
135.97%
RLAY
Relay Therapeutics
9.95
7.46
299.60%
IVA
Inventiva
5.55
2.45
79.03%
GHRS
GH Research
14.06
3.66
35.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.